MAISi vs. AQ Platform

Traditionally, the oversight of clinical trials at investigator sites has been a burdensome process, reliant on either the management of multiple shared spreadsheets or the high costs associated with software that often lacked relevance to the Australian setting. MAISi marks a significant advancement in this domain. Initially developed in 2001 as a data repository for clinical trials at a leading hospital, MAISi has evolved into a sophisticated workflow application aimed at optimizing various functions within research units. Acting as a centralized information hub, MAISi organizes data related to studies alongside the business units responsible for their management. This organized framework enhances the decision-making processes for management. Team members within each unit can access relevant information concerning their specific studies, patients, investigators, and study teams, while those with elevated access rights, such as Financial Officers and System Administrators, have the ability to retrieve detailed information across all units. Moreover, this efficient access not only fosters collaboration but also significantly boosts overall operational effectiveness, making MAISi an indispensable tool in modern clinical trial management. With its user-friendly design and tailored functionalities, MAISi is poised to redefine how clinical research is conducted in Australia.

The AQ Platform is a sophisticated software solution designed specifically for overseeing clinical research across various entities such as NHS trusts, clinical trial units, investigator sites, site networks, CROs, sponsors, and academic research organizations. It includes an array of modules that support trial management, electronic documentation for both trials and investigator sites, operations in pharmacies and laboratories, quality assurance, corrective and preventive actions (CAPA), along with the digital delegation of authority. This platform facilitates the seamless integration of regulated trial records and comprehensive audit trails, leading to improved efficiency in study operations. By harnessing Connected Intelligence, the software utilizes AI to pinpoint potential gaps and propose subsequent actions, with the stipulation that each recommendation must be validated by a designated user, thereby ensuring that customer data remains confidential and is not employed for AI model training. Hosted within the UK regions of Microsoft Azure, the AQ Platform is meticulously crafted to comply with ICH E6(R3) guidelines and meets the standards anticipated by the MHRA for Good Clinical Practice inspections. Furthermore, AQ Trials has received the NHS DSPT Standards Met (2026) designation and holds Cyber Essentials certification, underscoring its dedication to security and adherence to regulatory requirements. Created by physicians specializing in Phase 1 trials, the system offers the flexibility of individual module deployment, and it has been actively implemented in NHS operations since 2020, which highlights its effectiveness and reliability in practical clinical environments. The platform is continuously being enhanced based on user feedback, ensuring it adapts to the evolving demands of clinical research while maintaining high standards of performance and user satisfaction. As a result, it stands as a robust solution in the ever-changing landscape of clinical trial management.